Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
During persistent viral infections, chronic immune activation, negative immune regulator expression, an elevated interferon signature, and lymphoid tissue destruction correlate with disease progression. We demonstrated that blockade of type I interferon (IFN-I) signaling using an IFN-I receptor neutralizing antibody reduced immune system activation, decreased expression of negative immune regulatory molecules, and restored lymphoid architecture in mice persistently infected with lymphocytic choriomeningitis virus. IFN-I blockade before and after establishment of persistent virus infection resulted in enhanced virus clearance and was CD4 T cell-dependent. Hence, we demonstrate a direct causal link between IFN-I signaling, immune activation, negative immune regulator expression, lymphoid tissue disorganization, and virus persistence. Our results suggest that therapies targeting IFN-I may help control persistent virus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationIMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
Guidotti, L. G., & Chisari, F. V. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100230 · Cited by 811
Cited by
Items 301–400 of 759
Chang, Y.-H., Wang, K. C., Chu, K.-L., Clouthier, D., Tran, A., Perez, M. S. T., Zhou, A. C., Sater, A. A. A., & Watts, T. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.014 · Cited by 46
“However, IFN-I signaling is known to persist to the chronic stage of infection (Teijaro et al., 2013;Wilson et al., 2013).”
BackgroundNganou‐Makamdop, K., Billingsley, J. M., Yaffe, Z. A., O’Connor, G., Tharp, G. K., Ransier, A., Laboune, F., Matus‐Nicodemos, R., Lerner, A. M., Gharu, L., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007246 · Cited by 42
“T cell exhaustion is associated with persistent antigenic stimulation; many reports have previously highlighted that chronic type I IFN signaling during viral infections results in CD8 T cell exhaustion [21–23] and have shown that blocking IFN-I signaling restores T cell function in LCMV-infected mice [13, 14, 24].”
BackgroundGreene, T. T., & Zúñiga, E. I. (2021) · Viruses · doi:10.3390/v13091839 · Cited by 42
Xu, Z. Z., Kuhlmann-Hogan, A., Xu, S., Tseng, H., Chen, D., Tan, S., Sun, M. H., Tripple, V., Bosenberg, M., Miller‐Jensen, K., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4027 · Cited by 47
A Ceramide Analogue Stimulates Dendritic Cells To Promote T Cell Responses upon Virus Infections
Pritzl, C. J., Seo, Y., Xia, C., Vijayan, M., Stokes, Z. D., & Hahm, B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402672 · Cited by 41
Planès, R., Serrero, M. C., Leghmari, K., BenMohamed, L., & Bahraoui, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-35478-1 · Cited by 40
The Role of Interferon in Persistent Viral Infection: Insights from Murine Norovirus
Nice, T. J., Robinson, B. A., & Winkle, J. A. V. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.010 · Cited by 39
“In two separate studies, transient antibody blockade of IFNAR1 reduced production of the immunosuppressive cytokine, interleukin 10 (IL-10), increased CTL function, and enhanced viral clearance [43,44].”
BackgroundHarker, J. A., Wong, K. A., Dallari, S., Bao, P., Dolgoter, A., Jo, Y., Wehrens, E. J., Macal, M., & Zúñiga, E. I. (2018) · Journal of Virology · doi:10.1128/jvi.02196-17 · Cited by 39
Elsaesser, H. J., Mohtashami, M., Osokine, I., Snell, L. M., Cunningham, C. R., Boukhaled, G. M., McGavern, D. B., Zúñiga‐Pflücker, J. C., & Brooks, D. G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913776117 · Cited by 40
“We recently identified that type I interferons (IFN-I) lie at the nexus of these two programs, both providing the inflammatory signals necessary to initiate robust immunity, while reciprocally inducing negative regulatory mechanisms that suppress ongoing immune activation (2, 4, 5).”
BackgroundPietro, A. D., Polmear, J., Cooper, L., Damelang, T., Hussain, T., Hailes, L., O’Donnell, K., Udupa, V., Tian, M., Preston, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01077-y · Cited by 42
Sendai Virus Pathogenesis in Mice Is Prevented by Ifit2 and Exacerbated by Interferon
Wetzel, J. L., Fensterl, V., & Sen, G. C. (2014) · Journal of Virology · doi:10.1128/jvi.02201-14 · Cited by 40
“Blocking type I IFN action enabled virus clearance and restoration of a normal state of immune activation (36, 37).”
BackgroundFollicular CD8+ T Cells: Origin, Function and Importance during HIV Infection
Perdomo-Celis, F., Taborda, N. A., & Rugeles, M. T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01241 · Cited by 41
Effects of type I interferons in malaria
Sebina, I., & Haque, A. (2018) · Immunology · doi:10.1111/imm.12971 · Cited by 42
Eshleman, E. M., & Lenz, L. L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00431 · Cited by 42
“Type I IFNs were also associated with the induction of IL-10 secretion and Programed death-ligand 1 (PD-L1) expression by myeloid cells during chronic LCMV infection (109, 110).”
BackgroundResultInfluentialDivergent effects of type-I interferons on regulatory T cells
Piconese, S., Pacella, I., Timperi, E., & Barnaba, V. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.012 · Cited by 39
“Such chronic IFN signaling has been recently recognized as detrimental in a mouse model of chronic LCMV infection, by establishing an immunosuppressive program through the involvement of IL-10- and PD-L1-mediated signals in effector T cells [63,64].”
Lemos, H., Huang, L., McGaha, T. L., & Mellor, A. L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344407 · Cited by 35
Li, G., Zhao, J., Cheng, L., Jiang, Q., Kan, S., Qin, E., Tu, B., Zhang, X., Zhang, L., Su, L., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006505 · Cited by 37
Type I Interferon Receptor on NK Cells Negatively Regulates Interferon-γ Production
Lee, A. J., Mian, F., Poznanski, S. M., Stackaruk, M. L., Chan, T., Chew, M. V., & Ashkar, A. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01261 · Cited by 39
“found that blocking the type I IFN receptor during chronic LCMV infection was able to restore IFNγ production, suggesting that type I IFN can suppress antiviral effector functions (14).”
BackgroundInfluentialSelf-citationJean-Baptiste, V. S. E., Xia, C., Clare-Salzler, M. J., & Horwitz, M. S. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.014 · Cited by 39
T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases
McKinney, E. F., & Smith, K. G. (2016) · Immunology & Cell Biology · doi:10.1038/icb.2016.81 · Cited by 36
Gibb, D. R., Liu, J., Santhanakrishnan, M., Natarajan, P., Madrid, D. J., Patel, S. R., Eisenbarth, S. C., Tormey, C. A., Stowell, S. R., Iwasaki, A., et al. (2017) · Transfusion · doi:10.1111/trf.14288 · Cited by 36
Oh, J. H., Kim, M. J., Choi, S. J., Ban, Y. H., Lee, H. K., Shin, E., Lee, K.-M., & Ha, S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0403 · Cited by 37
“Although levels decline in the later phases of chronic infection due to numerous negative regulators (30), studies have shown that residual type I IFNs play an important role in preventing excessive T-cell activation LCMVmouse models (10, 11).”
BackgroundContext Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
Fox, L. E., Locke, M. C., & Lenschow, D. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606874 · Cited by 40
“org 5 negative immune regulators IL-10 and programmed deathligand 1 (PD-L1), increased protective adaptive immune responses, and accelerated clearance of persistent virus (78, 79, 105).”
BackgroundRappe, J. C. F., Finsterbusch, K., Crotta, S., Mack, M., Priestnall, S. L., & Wack, A. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201631 · Cited by 39
Jung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 39
Early Virus-Host Interactions Dictate the Course of a Persistent Infection
Sullivan, B. M., Teijaro, J. R., de la Torre, J. C., & Oldstone, M. B. A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004588 · Cited by 37
Self-citationThe interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?
Deeks, S. G., Odorizzi, P. M., & Sékaly, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci91916 · Cited by 36
“In this model, long-term viral control is mediated by decreased immune activation, decreased PD-1/PD-L1 activity, restored lymphoid architecture, and improved CD4+ T cell function (16, 17).”
BackgroundMa, X., Wang, Q., Sun, C., Agarwal, I., Wu, H., Chen, J., Zhao, C., Qi, G., Teng, Q., Yuan, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112944 · Cited by 37
Protozoan parasites and type I interferons: a cold case reopened
Beiting, D. P. (2014) · Trends in Parasitology · doi:10.1016/j.pt.2014.07.007 · Cited by 39
Schuler, B. A., Schreiber, M., Li, L., Mokrý, M., Kingdon, M. L., Raugi, D. N., Smith, C., Hameister, C., Racaniello, V. R., & Hall, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093897 · Cited by 35
IFN-λ Exerts Opposing Effects on T Cell Responses Depending on the Chronicity of the Virus Infection
Misumi, I., & Whitmire, J. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301705 · Cited by 38
Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses
Dickow, J., Francois, S., Kaiserling, R.-L., Malyshkina, A., Drexler, I., Westendorf, A. M., Lang, K. S., Santiago, M. L., Dittmer, U., & Sutter, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02255 · Cited by 39
Künzli, M., Reuther, P., Pinschewer, D. D., & King, C. G. (2021) · eLife · doi:10.7554/elife.61869 · Cited by 37
“infection rescues the Th1 effector compartment and improves viral control, although 215 this likely depends on the rate of viral replication(55-57).”
BackgroundA sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection
Lebratti, T. J., Lim, Y. S., Cofie, A., Andhey, P. S., Jiang, X., Scott, J. M., Fabbrizi, M. R., Ozantürk, A. N., Pham, C. T. N., Clemens, R. A., et al. (2021) · eLife · doi:10.7554/elife.65762 · Cited by 36
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury
Hackstein, C.-P., Spitzer, J., Symeonidis, K., Horvatic, H., Bedke, T., Steglich, B., Klein, S., Assmus, L. M., Odainic, A., Szlapa, J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.026 · Cited by 39
Padmanabhan, P., Garaigorta, U., & Dixit, N. M. (2014) · Nature Communications · doi:10.1038/ncomms4872 · Cited by 37
Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo
Abdel‐Mohsen, M., Deng, X., Liegler, T. J., Guatelli, J., Salama, M., Ghanem, H. E.-D. A., Rauch, A., Ledergerber, B., Deeks, S. G., Günthard, H. F., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02687-13 · Cited by 35
“infection suggest that IFN- is associated with both beneficial and detrimental disease outcomes and that the overall balance between the various, diverse effects of type I interferon ultimately determines the course of disease (14, 15).”
BackgroundTRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense
Wang, L., & Ning, S. (2021) · Viruses · doi:10.3390/v13020279 · Cited by 37
Guéry, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729233 · Cited by 34
“Here, blockade of IFN-I signaling even during the acute phase of infection facilitated a long-term viral clearance (56, 57).”
BackgroundReplication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
Hong, B., Sahu, U., Mullarkey, M. P., & Kaur, B. (2022) · Viruses · doi:10.3390/v14010118 · Cited by 34
“Type I interferon Activation of JAK–STAT1 and transcription of ISGs to inhibit virus infection [36,37]”
BackgroundComplex Regulation Pattern of IRF3 Activation Revealed by a Novel Dimerization Reporter System
Wang, Z., Ji, J., Peng, D., Ma, F., Cheng, G., & Qin, F. X.-F. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502458 · Cited by 35
Locke, M. C., Fox, L. E., Dunlap, B. F., Young, A. R., Monte, K. J., & Lenschow, D. J. (2021) · Journal of Virology · doi:10.1128/jvi.01143-21 · Cited by 33
Xing, J., Chai, Z., Ly, H., & Liang, Y. (2015) · Journal of Virology · doi:10.1128/jvi.01674-15 · Cited by 33
Wang, X., Caffrey-Carr, A. K., Liu, K.-W., Espinosa, V., Croteau, W., Dhingra, S., Rivera, A., Cramer, R. A., & Obar, J. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000802 · Cited by 34
Kharel, A., Shen, J., Brown, R. J., Chen, Y., Nguyen, C. P., Alson, D., Bluemn, T., Fan, J., Gai, K., Zhang, B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112649 · Cited by 35
“Additionally, a cluster containing STAT1 and STAT2 (motif accessibility heatmap cluster 4), which are both known TFs involved in IFN-I response, 58,60,61 showed enriched accessibility in the progenitor subset (Figure 6A).”
BackgroundCrimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
Özdarendeli, A. (2023) · Diagnostics · doi:10.3390/diagnostics13162708 · Cited by 34
“The disease resulting from the antibody-mediated IFN-I blockade model is almost identical to the disease observed in genetic knockout animals, with both displaying equivalent mean times to death.”
MethodInfluentialDiverse roles of lung macrophages in the immune response to influenza A virus
Li, H., Wang, A., Zhang, Y., & Wei, F. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1260543 · Cited by 42
“However, IFNα/β IFNα/β may be exacerbated during virus infection by hindering viral control (Guarda et al., 2011; Teijaro et al., 2013) or by causing inflammation and tissue damage that exacerbate the disease (Hogner et al.”
BackgroundImmunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 34
“…chromatin accessibility, while abrogating Type I IFN or IFN γ signaling in tumor cells improves the function of many immune compartments, such as CD8 + T cells, NK cells, and innate lymphoid cells (Benci et al, 2019; Benci et al, 2016; Qiu et al, 2023; Teijaro et al, 2013; Wilson et al, 2013).”
BackgroundTLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection
Hotz, C., Roetzer, L. C., Huber, T., Sailer, A. W., Oberson, A., Treinies, M., Heidegger, S. M., Herbst, T., Endres, S., & Bourquin, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500079 · Cited by 33
Giles, E. M., Sanders, T. J., McCarthy, N. E., Lung, J., Pathak, M., MacDonald, T. T., Lindsay, J., & Stagg, A. J. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.44 · Cited by 35
George, J., & Mattapallil, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00299 · Cited by 33
“On the other hand, blockade of chronic IFN signaling was shown to decrease immune activation and clear persistent LCMV infection in mice (55).”
BackgroundExhaustion and Inflation at Antipodes of T Cell Responses to Chronic Virus Infection
Čičin‐Šain, L., & Arens, R. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.11.012 · Cited by 32
Guo, K., Shen, G., Kibbie, J. J., González, T., Dillon, S. M., Smith, H., Cooper, E., Lavender, K. J., Hasenkrug, K. J., Sutter, K., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008986 · Cited by 33
B cell–derived IL-27 promotes control of persistent LCMV infection
Pratumchai, I., Žák, J., Huang, Z., Min, B., Oldstone, M. B. A., & Teijaro, J. R. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116741119 · Cited by 33
“This work was supported by NIH Grants R01AI164744 and R01AI118862 (to J.R.T.).”
BackgroundMethodSelf-citationType 1 Interferon in the Human Intestine—A Co-ordinator of the Immune Response to the Microbiota
Giles, E. M., & Stagg, A. J. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001078 · Cited by 33
Lack of Ikaros Deregulates Inflammatory Gene Programs in T Cells
Ana, C. L. D., Arakcheeva, K., Agnihotri, P., Derosia, N. M., & Winandy, S. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801270 · Cited by 32
de, M. M., Good, M. F., McCarthy, J. S., & Engwerda, C. R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600619 · Cited by 34
da Silva, J. G., Ferreira, D. P., Dumez, A., Wyss, T., Veber, R., Danilo, M., Pinschewer, D. D., Charmoy, M., & Held, W. (2023) · Science Immunology · doi:10.1126/sciimmunol.adh3113 · Cited by 34
Clouthier, D., Zhou, A. C., & Watts, T. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401002 · Cited by 33
Zeng, Z., Li, L., Chen, Y., Wei, H., Sun, R., & Tian, Z. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151218 · Cited by 32
“Recent studies indicate that chronic lymphocytic choriomeningitis virus infection can redirect IFN-α/β to induce negative immunity to support viral persistence instead of clearance (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundWang, B., Kang, W., Zuo, J., 康文臻, & Sun, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01431 · Cited by 36
Smith, J. A., Mathew, L., Gaikwad, A., Rech, B., Burney, M., Faro, J. P., Lucci, J. A., Bai, Y., Olsen, R. J., & Byrd, T. T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00173 · Cited by 31
Abdel-Hakeem, M. S. (2019) · Viruses · doi:10.3390/v11020106 · Cited by 32
“In chronic infection, there is a persistent elevated level of IFN-I in many contexts, and blocking IFN-I signaling enhances viral control [119,120].”
BackgroundSphingosine kinase 2 restricts T cell immunopathology but permits viral persistence
Studstill, C. J., Pritzl, C. J., Seo, Y., Kim, D. Y., Xia, C., Wolf, J. J., Nistala, R., Vijayan, M., Cho, Y., Kang, K. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci125297 · Cited by 30
AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections
Smith, J. A., Gaikwad, A., Mathew, L., Rech, B., Faro, J. P., Lucci, J. A., Bai, Y., Olsen, R. J., & Byrd, T. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881902 · Cited by 30
“8% (20) CR (complete response: HPV negative after 12 months of stopping AHCC) 10.”
BackgroundResultBénard, A., Mittelstädt, A., Klösch, B., Glanz, K., Müller, J., Schoen, J., Nüse, B., Brunner, M., Naschberger, E., Stürzl, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112637 · Cited by 31
Thompson, L. J., Lai, J.-F., Valladao, A. C., Thelen, T. D., Urry, Z., & Ziegler, S. F. (2016) · Nature Immunology · doi:10.1038/ni.3329 · Cited by 30
CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells
O’Brien, M. P., Manches, O., Wilen, C. B., Gopal, R., Huq, R., Wu, V., Sunseri, N., & Bhardwaj, N. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005553 · Cited by 30
Dysregulation of humoral immunity in chronic infection
Cooper, L., & Good‐Jacobson, K. L. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12338 · Cited by 30
Teh, C. E., Preston, S., Robbins, A. K., Stutz, M. D., Cooney, J. P., Clark, M. P., Policheni, A. N., Allison, C. C., Mackiewicz, L., Arandjelovic, P., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8041 · Cited by 30
Zander, R., Khatun, A., Kasmani, M. Y., Chen, Y., & Cui, W. (2022) · eLife · doi:10.7554/elife.80079 · Cited by 32
Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis
Lapierre, P., & Lamarre, A. (2015) · Journal of Immunology Research · doi:10.1155/2015/479703 · Cited by 31
“This is similar to the type I interferon paradox during chronic viral infections where interferon-α/β signaling can both limit early viral replication, through inhibition of viral transcription and translation and through degradation of viral nucleic acids while also suppressing immune responses later during infection…”
BackgroundCombining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Chiocca, E. A., Nakashima, H., & Nguyen, T. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66081 · Cited by 30
Knuschke, T., Rotan, O., Bayer, W., Kollenda, S., Dickow, J., Sutter, K., Hansen, W., Dittmer, U., Lang, K. S., Epple, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00614 · Cited by 28
“However, recent reports proposed also negative effects of constant IFN I signaling especially in the context of chronic viral infections, since it mediates immune dysfunction during persistent LCMV or chronic HIV infection of humanized mice (24, 25, 43).”
Molecular Basis of the Differentiation and Function of Virus Specific Follicular Helper CD4+ T Cells
Huang, Q., Hu, J., Tang, J., Xu, L., & Ye, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00249 · Cited by 30
“Several groups also demonstrated the skewed differentiation toward Tfh cells during chronic LCMV infection is firmly related to cytokines (such as IL-6/ IL-27) signaling through the IL-6 family receptor pathway (98, 99) .”
BackgroundComplexities of Type I Interferon Biology: Lessons from LCMV
Suprunenko, T., & Hofer, M. J. (2019) · Viruses · doi:10.3390/v11020172 · Cited by 33
“Yet, reduced virus load and enhanced viral clearance in these mice is not due to increased CD8+ cytotoxic T cell activity but is mediated by an enhanced CD4+ T cell response and IFN-γ-dependent mechanisms [9,70].”
BackgroundResultInfluentialThe transcription factor NFAT5 limits infection-induced type I interferon responses
Encabo, H. H., Traveset, L., Argilaguet, J. M., Angulo, A., Nistal‐Villán, E., Jaiswal, R., Escalante, C. R., Gekas, C., Meyerhans, A., Aramburu, J. F., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190449 · Cited by 31
“NFAT5 can enhance specific antipathogenic responses in TLR-activated macrophages by promoting expression of pro-inflammatory genes including Il1b (Buxadé et al., 2012; Tellechea et al., 2018), and this capacity could be modulated by its ability to repress IFN-I.”
BackgroundInfluentialA dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control
Namineni, S., O’Connor, T., Faure‐Dupuy, S., Johansen, P., Riedl, T., Liu, K., Xu, H. C., Singh, I., Shinde, P. V., Li, F., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.019 · Cited by 29
Xia, L., Wu, J., Pattaradilokrat, S., Tumas, K. C., He, X., Peng, Y., Huang, R., Myers, T. G., Long, C. A., Wang, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33599-1 · Cited by 27
Type I interferon underlies severe disease associated with Junín virus infection in mice
Hickerson, B. T., Sefing, E. J., Bailey, K. W., Wettere, A. J. V., Penichet, M. L., & Gowen, B. B. (2020) · eLife · doi:10.7554/elife.55352 · Cited by 30
“( Stifter and Feng, 2015 ), which has been shown to affect the development of an effective adaptive immune response and contributes to the inability of the host to resolve persistent LCMV infections ( Teijaro et al., 2013 ; Wilson et al., 2013 ).”
Gilroy, D. W. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00597-w · Cited by 27
Hajj, H. E., & Bazarbachi, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957535 · Cited by 29
Richert-Spuhler, L. E., & Lund, J. M. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.07.015 · Cited by 28
Dorhoi, A., Iannaccone, M., Maertzdorf, J., Nouailles, G., Weiner, J. M., & Kaufmann, S. H. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00036 · Cited by 29
Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection
Li, Y., Sun, B., Eßer, S., Jessen, H. K., Streeck, H., Widera, M., Yang, R., Dittmer, U., & Sutter, K. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0076 · Cited by 27
Carnathan, D. G., Lawson, B., Yu, J., Patel, K., Billingsley, J. M., Tharp, G. K., Delmas, O. M., Dawoud, R. A., Wilkinson, P. A., Nicolette, C. A., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01760-17 · Cited by 27
Etiology and Pathogenesis of Systemic Lupus Erythematosus
Crow, M. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00079-6 · Cited by 31
Decoding the complexity of type I interferon to treat persistent viral infections
Wilson, E. B., & Brooks, D. G. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.10.003 · Cited by 26
Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination
Zhong, C., Liu, F., Hajnik, R. L., Lei, Y., Chen, K., Wang, M., Liang, Y., Sun, J., Soong, L., Hou, W., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00925-21 · Cited by 27
Innate Antiviral Defenses Independent of Inducible IFNα/β Production
Paludan, S. R. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.06.003 · Cited by 29
Pleiotropic Roles of Type 1 Interferons in Antiviral Immune Responses
Teijaro, J. R. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.08.001 · Cited by 29
“Importantly, blockade of IFNAR1 both prior to and following established persistent LCMV infection promoted faster virus clearance and required an intact CD4 T cell compartment (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundInfluentialSelf-citationType I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection
Daugan, M., Murira, A., Mindt, B. C., Germain, A., Tarrab, E., Lapierre, P., Fritz, J. H., & Lamarre, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00564 · Cited by 26
“As depicted in Figure 5A, LCMV-specific-binding Ab responses were not significantly affected by IFNAR blockade as observed in previous reports (16, 17).”
BackgroundResultInfluentialCubas-Gaona, L. L., Díaz-Beneitez, E., Ciscar, M., Rodrígúez, J. F., & Rodríguez, D. (2018) · Journal of Virology · doi:10.1128/jvi.00364-18 · Cited by 31
“Human immunodeficiency virus (78), lymphocytic choriomeningitis virus (79, 80), classical swine fever virus (81), Newcastle disease virus (82), avian influenza virus (58), and SARS coronavirus (57) are representative examples of this direct relationship between the type I IFN response and the rigor of the clinical out…”
BackgroundEbola Immunity: Gaining a Winning Position in Lightning Chess
Ploquin, A., Zhou, Y., & Sullivan, N. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700827 · Cited by 26
“detrimental, as observed in chronic lymphocytic choriomeningitis virus infection, in which CD8 T cell exhaustion is driven by immune activation and the upregulation of inhibitory receptors (59, 60).”
BackgroundInfectious Diseases and the Lymphoid Extracellular Matrix Remodeling: A Focus on Conduit System
Morgado, F. N., da Silva, A. V. A., & Porrozzi, R. (2020) · Cells · doi:10.3390/cells9030725 · Cited by 28
“In the presence of IFN-I, cellular exhaustion is induced through PD-L1 and IL-10 expression inhibiting the response of virus-specific CD8+ T cells and favoring virus persistence [63,64].”
BackgroundSacramento, L. A., Benevides, L., Maruyama, S. R., Tavares, L., Fukutani, K. F., Francozo, M., Sparwasser, T. D., Cunha, F. Q., de Almeida, R. P., Silva, J. S., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008435 · Cited by 26
“Suppressive factors play a dominant role since their absence decreases the expression of IL-10 and PDL1 and promotes viral clearance in an IFN-γ-producing CD4 T-cell-dependent manner [43,69].”
BackgroundContext-dependent impact of type I interferon signaling in cancer
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L., & Mañes, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02495-4 · Cited by 27
“Further corroborating the notion that type I IFN signaling may de facto limit proficient immune responses in some contexts, blocking IFNAR signaling with a monoclonal antibody has been shown to improve the control of persistent lymphocytic choriomeningitis virus infection (LCMV) in mice [124, 125].”
Edwards, C. L., Best, S. E., Gun, S. Y., Claser, C., James, K. R., de, M. M., Sebina, I., Rivera, F. D. L., Amante, F. H., Hertzog, P. J., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444824 · Cited by 25
Swainson, L. A., Sharma, A., Ghneim, K., Ribeiro, S. P., Wilkinson, P. A., Dunham, R. M., Albright, R. G., Wong, S., Estes, J. D., Piatak, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153046 · Cited by 25
“By contrast, TI-IFN inhibition during chronic LCMV disease diminished chronic immune activation while also restoring lymphoid tissue architecture and immune responses that ultimately facilitated viral clearance (21–24).”
Protective versus Pathogenic Type I Interferon Responses during Virus Infections
Jung, K. I., McKenna, S., Vijayamahantesh, V., He, Y., & Hahm, B. (2023) · Viruses · doi:10.3390/v15091916 · Cited by 29
“Intriguingly, blockade of type I IFN signaling using anti-IFNAR1 antibody during LCMV Cl 13 chronic infection relieved T cell suppression and led to accelerated clearance of viral infection [77,78].”
Background
Metadata
- Authors
- Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A.
- Affiliations
- Scripps Research Institute (US)
- Washington University in St. Louis (US)
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
- Corresponding author
- Teijaro, John R.
- Ng, Cherie
- Oldstone, Michael B. A.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3640797
- OpenAlex
- W2024556668
- Cited by
- 755
- References
- 38
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 39 · 2023: 40 · 2022: 42 · 2021: 49 · 2020: 56 · 2019: 55 · 2018: 55 · 2017: 73 · 2016: 86 · 2015: 80 · 2014: 71 · 2013: 37
- FWCI
- 50.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ns041219-10, 5t32ai007354-30)
- National Heart, Lung, and Blood Institute (HL007195, T32HL007195)
- National Cancer Institute (R01CA043059, CA-43059, R37CA043059)
- National Institute of Allergy and Infectious Diseases (AI-077719, AI09484, AI-047140, R01AI009484, AI007354, R01AI047140, T32-AI007354., R56AI077719, R01AI077719, U54AI057160)
- National Institute of Neurological Disorders and Stroke (T32-NS041219, NS-041219)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- lymphocytic choriomeningitis virus, viral persistence, type I interferon signaling, immune activation, negative immune regulation, CD4+ T cells, viral clearance, antiviral therapy
- MeSH terms
- Animals, Antibodies, Viral, Arenaviridae Infections, Dendritic Cells, Female, Immune Tolerance, Interferon Type I, Lymphocytes, Lymphocytic choriomeningitis virus, Male, Mice, Inbred C57BL, Spleen, Viremia, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.